Lung cancer: multidisciplinary approach to tissue sampling.
Radiologic clinics of North America, 50, 951-60 (2012)
Setting up a lung cancer screening program.
Journal of the National Comprehensive Cancer Network : JNCCN, 10, 277-85 (2012)
Macrophage migration inhibitory factor promotes tumor growth in the context of lung injury and repair.
American journal of respiratory and critical care medicine, 182, 1030-7 (2010)
Seminars in respiratory and critical care medicine, 32, 52-61 (2011)
The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma.
American journal of clinical pathology, 136, 564-71 (2011)
Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer.
The American journal of pathology, 174, 638-46 (2009)
Diversity of the angiogenic phenotype in non-small cell lung cancer.
American journal of respiratory cell and molecular biology, 36, 343-50 (2007)
Chemokines as therapeutic targets in non-small cell lung cancer.
Current medicinal chemistry. Anti-cancer agents, 2, 403-17 (2002)
Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis.
Clinical cancer research : an official journal of the American Association for Cancer Research, 9, 853-60 (2003)
PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer.
Neoplasia (New York, N.Y.), 7, 294-301 (2005)
RANTES expression is a predictor of survival in stage I lung adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, 8, 3803-12 (2002)
Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity.
Journal of immunology (Baltimore, Md. : 1950), 166, 7549-55 (2001)
Monocyte-fibronectin interactions, via alpha(5)beta(1) integrin, induce expression of CXC chemokine-dependent angiogenic activity.
Journal of immunology (Baltimore, Md. : 1950), 167, 5362-6 (2001)
Improved survival in tumor-bearing SCID mice treated with interferon-gamma-inducible protein 10 (IP-10/CXCL10).
Cancer immunology, immunotherapy : CII, 50, 533-8 (2001)
Integrin alpha4beta1 regulates migration across basement membranes by lung fibroblasts: a role for phosphatase and tensin homologue deleted on chromosome 10.
American journal of respiratory and critical care medicine, 168, 436-42 (2003)
Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis.
Biochemical and biophysical research communications, 210, 51-7 (1995)
Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases.
The Journal of experimental medicine, 184, 981-92 (1996)
Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer.
The Journal of clinical investigation, 102, 465-72 (1998)
The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis.
Journal of immunology (Baltimore, Md. : 1950), 159, 1437-43 (1997)
Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines.
Cancer immunology, immunotherapy : CII, 49, 63-70 (2000)